Description

Tarloxotinib Bromide CAS NO 1636180-98-7 is a potent and selective small molecule inhibitor of the c-Met (MET) receptor tyrosine kinase, which plays a critical role in cellular signaling pathways associated with tumor growth and metastasis. This compound is a key advanced intermediate in the synthesis of novel therapeutic agents targeting various cancers, particularly non-small cell lung cancer (NSCLC). It is essential for pharmaceutical R&D laboratories, contract research organizations (CROs), and manufacturers engaged in the development of precision oncology drugs and targeted therapies.

Application

• Pharmaceutical Intermediate: Primary use as a critical building block in the synthesis of the investigational drug Tarloxotinib (TH-4000).
• Oncology Research: Used in preclinical and clinical-stage research for developing hypoxia-activated prodrugs targeting the c-Met pathway.
• Biochemical Assay Development: Serves as a reference standard and active pharmaceutical ingredient (API) in assay development for kinase inhibition studies.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for GMP-scale production of clinical trial materials.
• Academic Research: Utilized in university and institutional labs studying MET-driven tumorigenesis and resistance mechanisms.
• Drug Discovery Libraries: Incorporated into screening libraries for identifying new anti-cancer compounds with similar mechanisms of action.

Basic Information

Product Name	Tarloxotinib Bromide
CAS No.	1636180-98-7
Molecular Formula	C₂₈H₂₈BrN₅O₃
Molecular Weight	562.46 g/mol
Synonyms	TH-4000 Bromide; (E)-N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Bromide; Tarloxotinib (TH4000) Bromide; C-Met Inhibitor Bromide Salt; PF-04254644 Bromide (related analog); UNII-8V71L5A2FJ; Cyclopropane-1,1-dicarboxamide, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-, (E)-, monobromide
EINECS	Contact for details

Quality Control

Our Tarloxotinib Bromide is manufactured under strict quality systems to ensure high purity and batch-to-batch consistency suitable for research and pharmaceutical development. Each batch is accompanied by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles. We adhere to relevant ICH guidelines and can supply material that meets specifications for use in GLP (Good Laboratory Practice) and cGMP (current Good Manufacturing Practice) environments upon request.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) in a dry, cool, and well-ventilated place. The product is hygroscopic (moisture-sensitive) and must be kept under an inert atmosphere (e.g., nitrogen or argon) after opening to maintain stability and prevent degradation.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥98.0%
Water Content (KF)	≤1.0%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm
Single Unknown Impurity (HPLC)	≤0.5%
Total Impurities (HPLC)	≤2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.